Halozyme Therapeutics recommended for European Commission approval San Diego Source (subscription) The treatment is Roche's subcutaneous formulation of MabThera (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20). “This subcutaneous formulation of MabThera, pending approval in the EU, provides a new route of administration ... Halozyme Announces Positive Opinion From CHMP For European Approval Of ... |
